Connect with us

Fertility

Fairtility integrates with leading electronic medical record systems in the reproductive care market

Fairtility’s software platform supports reproductive care practitioners as a workflow enhancement and decision support toolset

Published

on

Fairtility, the transparent AI innovator powering reproductive care for improved outcomes, has announced that its AI decision support system, CHLOE™, has been successfully integrated with leading electronic medical record (EMR) platforms used in fertility clinics, including vRepro, IDEAS from Mellowood Medical, nAble IVF and MedITEX.

“Integrating Fairtility’s CHLOE with the top EMR platforms enables clinics to seamlessly consolidate and standardize all data from both clinical and operational sources, moving us towards digital transformation of reproductive care,” said Eran Eshed, CEO and co-founder of Fairtility.

“These integrations enable information to flow seamlessly, maximizing clinic and lab efficiency and transforming both the patient and clinician experience.”

Fairtility’s AI-powered software platform, CHLOE, supports reproductive care practitioners as a workflow enhancement and decision support toolset.

Integrating CHLOE with EMRs facilitates digitalisation of the embryology lab, allowing for live, automatic data capture and processing within interconnected systems.

The result is a unified data and insights hub for fertility clinics that continuously captures and interprets data straight from the source.

This facilitates streamlined and automated clinical workflows to ensure efficient operations within embryology labs. With real time data flowing securely between systems, reproductive care practitioners see all key information to maximise patient care and outcomes.

“The seamless transfer of time-lapse sourced embryology images and annotations via Fairtility [CHLOE] to the IDEAS EMR, combined with broader data sets, facilitates clinical decisions by our clients,” explained Mark Marcon, president at Mellowood Medical IDEAS EMR.

Key benefits of CHLOE’s integration with the EMR platforms include:

  • Digitalization of the clinic – Integration of EMRs with CHLOE technology standardises KPI data inputs and comparisons, enabling clinics to make informed decisions based on accurate and complete verified data, continuously updating directly from the source to improve operational performance. 
  • Enhancing clinical decision making – EMR integration with CHLOE ensures completeness and accuracy of live data collection across clinics’ networks, bringing consistency and transparency to embryo quality assessment and selection.
  • Reducing administrative burden and optimising workflows – Integrating CHLOE into EMR systems reduces administrative burdens on embryologists by enabling seamless communication between systems. This streamlines workflows, resulting in up to 30 per cent reduction in administrative work. As a result, embryologists can manage an average of 50 per cent more cycles, leading to increased productivity and efficiency.
  • Improving the patient experience – With access to all key information in a unified platform, clinicians are empowered to have transparent dialogue with patients on treatment decisions with the confidence that they have not missed any patient data that could impact care for an enhanced patient experience.

“I believe the IVF lab of the future needs to be a streamlined source of priceless data combining the latest technologies like Artificial Intelligence and Next Generation Sequencing (genetics), enabling our staff to consistently make the best clinical choices and personalise each treatment,” said Adriano Carbone, head of group biobank and industry relations and country manager Spain and Portugal for Next Fertility Clinics.

“This can only be achieved with full integration of the different systems used in the lab and combined with the clinical data and outcomes via the medical EMR.

“The present is that our clinical care teams are already reaping the benefits of this integration with streamlined workflows, reduced administrative time, and minimized note work in the IVF lab, enabling our team to be more effective, and serve more patients with greater accuracy and transparency.”

Insight

Covid vaccine not linked to decrease in childbirth, study finds

Published

on

The Covid vaccine is not behind a fall in childbirth, a Swedish study has shown.

Rumours on social media have alleged that the jab impairs chances of becoming pregnant.

In the later stages of the pandemic, some countries, including Sweden, saw fewer births, raising the question of whether vaccines were responsible.

The study analysed all women aged 18 to 45 years in Region Jönköping County, Sweden, a total of almost 60,000 women. Of these, 75 per cent were vaccinated once or more against Covid-19 from 2021 to 2024.

Researchers at Linköping University used healthcare records on childbirths, miscarriages and deaths.

Comparing vaccinated and unvaccinated groups, the researchers found no statistically significant differences in childbirths or miscarriages.

This aligns with previous studies finding no link between the Covid vaccine and fertility.

 Toomas Timpka is professor of social medicine at Linköping University.

Timpka said: “We see no difference in childbirth rates between those who have taken the vaccine and those who haven’t.

“We’ve also looked at all registered miscarriages among those who became pregnant, and we see no difference between the groups there either.

“Our conclusion is that it’s highly unlikely that the mRNA vaccine against COVID-19 was behind the decrease in childbirth during the pandemic.”

The researchers suggest other explanations for the dip in births.

People now in their 30s were born in the late 1990s, a period of economic strain and lower birth rates in Sweden, shrinking today’s cohort of potential parents.

Additional pandemic-related factors, such as health and economic concerns and changed behaviour during lockdown, may also have reduced childbirth.

A strength of the study is its large, nationally representative cohort.

The analysis adjusted for age to avoid masking any potential vaccine effect on childbirth.

Continue Reading

Insight

Parents sue IVF clinic after delivering someone else’s baby

Published

on

A Florida couple have sued an IVF clinic after giving birth to a baby who is not genetically related to either of them.

Tiffany Score and Steven Mills hired IVF Life, which operates as the Fertility Center of Orlando in Longwood to help them conceive about five years ago using in vitro fertilisation.

The couple had an embryo implanted in April and welcomed a baby girl nine months later, but soon suspected the clinic had made an error.

Both Score and Mills are white, but the baby had the appearance of a racially non-Caucasian child, according to the lawsuit.

Genetic testing confirmed that the baby is not biologically theirs. The couple filed the lawsuit on 22 January after allegedly trying to contact the clinic multiple times without getting a response.

Jack Scarola, one of the couple’s lawyers, told the Orlando Sentinel: “They have fallen in love with this child. They would be thrilled in the knowledge that they could raise this child.

“But their concern is that this is someone else’s child, and someone could show up at any time and claim the baby and take that baby away from them.”

Score and Mills are also concerned that one of the three fertilised eggs they had frozen at the clinic may have been mistakenly implanted into someone else.

They have demanded that the clinic share what happened with all other patients who had embryos stored at the facility during the year before Score gave birth. They also want IVF Life to pay for genetic testing of every child born as a result of its services over the last five years, and to account for their remaining embryos.

The couple said in a statement: “We love our little girl. We would hope to be able to continue to raise her ourselves with confidence that she won’t be taken away from us.

“At the same time, we are aware that we have a moral obligation to find and notify her biological parents, as it is in her best interest that her genetic parents are provided the option to raise her as their own.”

A family spokesperson said: “Based upon leads discovered to date, and despite the lack of help or cooperation from the clinic, there is hope that we will be able to introduce our daughter to her genetic parents and to find our own genetic child soon.”

The lawsuit names IVF Life LLC and Dr Milton McNichol, who runs the clinic.

The Fertility Center of Orlando had posted a notice on its website stating it is “actively cooperating with an investigation to support one of our patients in determining the source of an error that resulted in the birth of a child who is not genetically related to them.”

The notice was removed after a court hearing on Wednesday.

During the hearing, the judge ordered the clinic to submit a thorough plan for handling the situation by Friday.

McNichol was reprimanded by Florida’s Board of Medicine in May 2024 after an inspection of the clinic in June 2023 revealed several issues, including equipment that did not meet current performance standards, failure to comply with a risk-management plan and missing medication.

He was fined US$5,000.

Continue Reading

Fertility

Femtech World Awards to celebrate breakthrough fertility innovations

Published

on

Fertility innovation is to set to take centre stage at Femtech World’s third annual awards event.

The Femtech World Awards will celebrate some of the best examples of leadership, innovation and impact in key areas that affect women’s health and wellbeing.

The Fertility Innovation of the Year award celebrates a pioneering product, service or initiative that is transforming fertility care and support.

The winner will have demonstrated exceptional innovation in helping individuals or couples navigate fertility journeys, whether through technology, treatments, education, accessibility, or emotional support.

Consideration will be given to scientific advancement, inclusivity, user impact and the ability to break barriers in fertility health.

The award is sponsored by FinDBest IVF – a global B2B digital platform created to simplify and accelerate how IVF and ART manufacturers connect with trusted, pre-vetted distributors around the world.

Launched in 2024, the platform addresses a long-standing challenge in the MedTech sector—fragmented, costly, and inefficient market access—by offering a curated, country-specific directory of active partners, complete with key segmentation, certification indicators, and direct contact tools.

From consumables and lab equipment to AI-powered embryo selection and genetic testing solutions, FinDBest makes it faster and easier for companies to scale internationally—without relying on expensive congresses or cold outreach.

Juan A. Jiménez is founder and CEO of FinDBest IVF.

He said: “As part of its commitment to driving smarter access to reproductive innovation, FinDBest IVF is proudly supporting the Femtech World Fertility Innovation Awards for the second year in a row.

“This collaboration reflects two core beliefs at the heart of the platform.

“First, FinDBest IVF was created to accelerate not only the discovery of innovative fertility solutions but their global adoption.

“By supporting these awards, the platform helps amplify breakthrough technologies—from AI-based egg quality tools to next-gen IVF microdevices—and ensures they can reach the right partners and clinics faster.

“Second, the Awards align with FinDBest’s vision of building a 360-degree commercialisation ecosystem, where innovation is not just recognised, but connected to real-world opportunities.

“Many award nominees are pioneering startups and clinical researchers—exactly the kind of innovators who benefit from FinDBest’s support in navigating regulatory complexity, distributor validation, and go-to-market strategies across diverse regions.

“Together with Femtech World, FinDBest IVF is helping to spotlight, support, and scale the future of fertility care.”

Find out more about the Femtech World Awards and enter for free here.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.